A comprehensive review of the scientific literature on the possible benefits of CBD, describing findings from both preclinical and human clinical studies.
CBD (cannabidiol), a nonintoxicating compound derived from the cannabis plant, can be found in products ranging from lotion and smoothies to chewable gummies and pet treats. It's been promoted—but not always scientifically validated—as a treatment for medical conditions including psychosis, anxiety, pain, and even cancer. In this book, three leading cannabis researchers look at the science of CBD, offering a comprehensive review of the scientific literature on the possible benefits of CBD and describing their findings from both preclinical and human clinical studies.
As it turns out, the current CBD fad has some basis in preclinical animal research that indicates potential beneficial effects. Clinical studies, hampered by regulations governing research with cannabis, have lagged behind the basic animal research. The authors examine what research shows about chemical and pharmacological aspects of CBD and CBD's interaction with THC, the main psychotropic compound found in cannabis. They go on to review the current state of knowledge about CBD's effectiveness in treating epilepsy, cancer, nausea, pain, anxiety, PTSD, depression, sleep disorders, psychosis, and addiction.
CBD is a topic surrounded by anecdote and hype, but this book offers an accessible, timely and even-handed evaluation of evidence. Without overselling or pushing a particular agenda (problems that are rife in the cannabis field), the book raises critical scientific issues and is an important and interesting contribution to the literature.
Margaret Haney, Director of the Cannabis Research Laboratory and Professor of Neurobiology at the Columbia University Irving Medical Center
Cannabinoid science is novel and the market has grown at a faster rate than research and regulation. This book provides a comprehensive, fact-based summary that is desperately needed by consumers, patients, practitioners, and policy makers to inform important decisions.
Shawn Hauser, Partner, Vicente Sederberg LLP
Funding provided by: D2O